小剂量阿替普酶静脉溶栓后急性缺血性脑卒中患者的神经保护价值探讨

Neuroprotective value of low-dose alteplase in patients with acute ischemic stroke after intravenous thrombolysis

目的探究小剂量阿替普酶静脉溶栓治疗急性缺血性脑卒中应用疗效及对神经保护作用分析。方法选取我院神经内科2019年3月至2019年12月收治急性缺血性脑卒中患者进行数据比对,共计110例,采用随机数字表法分组,参照组55例,采用标准剂量阿替普酶静脉溶栓治疗,观察组55例,采用小剂量阿替普酶静脉溶栓治疗。结果治疗前2组患者NIHSS评分具有一致性,治疗后2组患者NIHSS评分较比治疗前降低,观察组降低幅度大于参照组(P<0.05);观察组患者治疗期间消化道出血、牙龈出血、脑出血不良反应发生率低于参照组(P<0.05);观察组患者治疗后Barthel评分、FMA评分高于参照组(P<0.05)。结论小剂量阿替普酶于急性缺血性脑卒中静脉溶栓应用疗效优于标准剂量,具有高效、安全等应用优势。

Objective To explore the effect and neuroprotective effect of intravenous thrombolytic therapy with low-dose alteplase on acute ischemic stroke.Methods A total of 110 patients with acute ischemic stroke admitted to the Department of Neurology in our hospital from March 2019 to December 2019 were selected and compared,the patients were treated with standard dose of Alteplase,and 55 patients in the observation group were treated with small dose of alteplase.Results The NIHSS scores of the two groups were consistent before treatment.After treatment,the NIHSS scores of the two groups were lower than that of the Control Group(P<0.05)The incidence of gastrointestinal bleeding,gingival hemorrhage and cerebral hemorrhage in the observation group was lower than that in the Control Group(P<0.05),and the Barthel score and FMA score in the observation group were higher than those in the Control Group(P<0.05).Conclusion low-dose alteplase is superior to standard dose in intravenous thrombolytic therapy for acute ischemic stroke,and has the advantages of high efficiency and safety.